Literature DB >> 31445851

Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data.

Jeanny B Aragon-Ching1, Amanda Nizam2, Donald E Henson3.   

Abstract

BACKGROUND: Urothelial carcinomas are the most common malignant tumors in the upper and lower urinary tract. Renal cell carcinomas (RCCs) have a different pathoepidemiologic incidence and characteristics. We describe a population-based approach of differentiating between urothelial and renal carcinomas as a basis to support shared morphologic phenotypes.
MATERIALS AND METHODS: Data from 2000 through 2014 from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute were used to calculate the incidence rates for cancers of the kidney, renal pelvis, ureter, and urinary bladder. Graphic plots of the epidemiologic patterns were analyzed according to age frequency density and double logarithmic (log-log) plots of age-specific incidence rates and age of diagnosis.
RESULTS: RCCs were initially more common than cancers of the urinary bladder, but after age 60, cancers of the bladder became more common with age-specific rates rapidly rising in all age groups. The age frequency density plot for RCC peaked earlier than for urothelial cancers indicating a different tumorigenic process. Log-log plots revealed near parallel proportional rate patterns for cancers of the renal pelvis, ureters, and urinary bladder, suggesting similar carcinogenic pathways among these tumors, whereas they were not parallel for RCCs. Similar slopes indicate that cancer incidence is increasing at similar rates regardless of the incidence of each cancer.
CONCLUSION: Tumors that arise in the renal pelvis, ureters, and urinary bladder share a common carcinogenic field on the basis of pathoepidemiologic analysis. The definition of a carcinogenic field should expand to include epidemiological parameters as well as common morphologic and embryological patterns.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinogenesis; Epidemiology; Field effect; Tumor registration; Urothelial carcinomas

Mesh:

Year:  2019        PMID: 31445851     DOI: 10.1016/j.clgc.2019.07.011

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  5 in total

1.  A Novel M7G-Related MicroRNAs Risk Signature Predicts the Prognosis and Tumor Microenvironment of Kidney Renal Clear Cell Carcinoma.

Authors:  Peng Hong; Huifang Du; Ming Tong; Qingfei Cao; Ding Hu; Jiaji Ma; Yanyang Jin; Zizhi Li; Weichao Huang; Guangquan Tong
Journal:  Front Genet       Date:  2022-06-24       Impact factor: 4.772

2.  The incidence and prevalence of upper tract urothelial carcinoma: a systematic review.

Authors:  Ahmed Soualhi; Elke Rammant; Gincy George; Beth Russell; Deborah Enting; Rajesh Nair; Mieke Van Hemelrijck; Cecilia Bosco
Journal:  BMC Urol       Date:  2021-08-17       Impact factor: 2.264

3.  Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.

Authors:  Kari Hemminki; Asta Försti; Akseli Hemminki; Börje Ljungberg; Otto Hemminki
Journal:  PLoS One       Date:  2022-01-04       Impact factor: 3.240

4.  Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.

Authors:  David D'Andrea; Surena Matin; Peter C Black; Firas G Petros; Homayoun Zargar; Colin P Dinney; Michael S Cookson; Wassim Kassouf; Marc A Dall'Era; John S McGrath; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeffrey M Holzbeierlein; Trinity J Bivalacqua; Srikala S Sridhar; Scott North; Daniel A Barocas; Yair Lotan; Andrew J Stephenson; Bas W van Rhijn; Philippe E Spiess; Siamak Daneshmand; Shahrokh F Shariat
Journal:  BJU Int       Date:  2020-10-14       Impact factor: 5.588

5.  Bladder and upper urinary tract cancers as first and second primary cancers.

Authors:  Guoqiao Zheng; Kristina Sundquist; Jan Sundquist; Asta Försti; Otto Hemminki; Kari Hemminki
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.